
Aditya Birla Capital Analyst Review 2027: A 38% Profit Jump, a Stock Near Its High and Only Two Published Targets
Updated: 17 Nov 2026 • 2:07 pm
Posted by:

Aditya Birla Capital Stock Snapshot (16 Nov 2026 close)
- Current Market Price (CMP): ₹408.50
- 52-Week High / Low: ₹430.70 / ₹287.70
- Market Capitalisation: ₹1,11,689 crore
- P/E Ratio vs Industry P/E: 24.3 vs 18.0
- Latest Quarter (Q2 FY27) Revenue: ₹16,545 crore (consolidated)
- Latest Quarter (Q2 FY27) Net Profit: ₹1,288 crore (consolidated)
Quick Answer: The Aditya Birla Capital analyst review 2027 rests on a strong September quarter: consolidated revenue rose 31% to ₹16,545 crore and profit after tax rose 38% to ₹1,288 crore. Only two dated brokerage targets could be verified, Motilal Oswal's ₹480 (Buy) and Sharekhan's ₹407 (Positive), and both came before these results. At ₹408.50 the stock sits about 5% below its 52-week high, so the published upside now ranges from almost nothing to about 17%. The real debate is whether lending growth near 25% can keep running while the AMC and health insurance arms cool.
The Aditya Birla Capital analyst review 2027 begins with a quarter that beat the company's own recent run rate. For readers tracking the Aditya Birla Capital share price target 2027, the September 2026 quarter produced consolidated profit after tax of ₹1,288 crore, up 38% from ₹934 crore a year earlier, while return on equity climbed to 15.9% from 14.2%.
Aditya Birla Capital closed at ₹408.50 on 16 November 2026, a little under its 52-week high of ₹430.70 and about 42% above its low of ₹287.70. This Aditya Birla Capital analyst review 2027 covers the published brokerage views, the quarter in detail, how each business earns, and what could move the Aditya Birla Capital stock outlook 2027 from here.
Click Here – Get Free Investment Predictions
What Analysts Are Saying in the Aditya Birla Capital Analyst Review 2027
Coverage of the stock is wider than this table suggests, but only two targets could be traced to a dated, named report. Both were published before the Q2 FY27 numbers came out on 30 October 2026, so read them as the latest positions we can verify, not as reactions to the quarter.
| Brokerage | Rating | Target Price | Date |
|---|---|---|---|
| Motilal Oswal Financial Services | Buy | ₹480 | August 2026 |
| Sharekhan (Mirae Asset Sharekhan) | Positive | ₹407 | March 2026 |
Motilal Oswal builds its ₹480 figure on a sum-of-the-parts method, valuing the lending, insurance and asset management arms separately to March 2028. Sharekhan's ₹407 is older and has already been met, which says more about how far the stock has run than about any change in the business.
So the honest summary of this Aditya Birla Capital analyst review 2027 is that the one recent brokerage target implies roughly 17% upside, while the older one is behind the price. Fresh notes after the Q2 print should reset these numbers for the Aditya Birla Capital share price target 2027.
Latest Results Behind the Aditya Birla Capital Analyst Review 2027
| Metric | Q2 FY27 | Q2 FY26 | Change |
|---|---|---|---|
| Consolidated Revenue | ₹16,545 crore | ₹12,598 crore | +31% |
| Consolidated Profit After Tax | ₹1,288 crore | ₹934 crore | +38% |
| Return on Equity | 15.9% | 14.2% | +1.7 pts |
| NBFC Gross Revenue | ₹5,179 crore | Base year figure | +25% |
| Health Insurance Gross Premium | ₹2,346 crore | Base year figure | +46% |
Lending did most of the work in this Aditya Birla Capital analyst review 2027 quarter. The NBFC book kept compounding, and the housing finance arm reached assets under management of ₹57,373 crore with a return on assets of 2.12%, a level that management had promised for some time. Stage 3 assets stayed near multi-quarter lows, which matters because a lender's profit can vanish quickly if credit costs jump.
Not everything in the Aditya Birla Capital analyst review 2027 rose. Profit from the asset management business fell about 27% from the June quarter, the health insurance result dipped, and the share of profit from joint ventures fell about 29%. The soft spots were small enough to absorb this time.
How Aditya Birla Capital Makes Money
ABCL is the financial services holding arm of the Aditya Birla group, and Grasim Industries alone owns 52.99% of it. Its earnings come from four main engines:
- Lending (NBFC): loans to individuals, small businesses and mid-sized companies. After the merger of Aditya Birla Finance into the parent, this book sits directly inside ABCL.
- Housing finance: home loans through Aditya Birla Housing Finance, with a growing affordable segment.
- Asset management: a stake in the listed Aditya Birla Sun Life AMC, which earns fees on mutual fund assets.
- Insurance: life insurance through Aditya Birla Sun Life Insurance and health insurance through Aditya Birla Health Insurance.
Lending earns the spread between what borrowers pay and what ABCL pays for funds. Insurance and asset management earn premiums and fees, and they need far less balance sheet. That mix is why the Aditya Birla Capital analyst review 2027 gets valued in parts; the lending arm is judged on price to book value, while the fee businesses are judged on earnings.
Growth Triggers in the Aditya Birla Capital Analyst Review 2027
Four triggers stand out in the Aditya Birla Capital analyst review 2027:
- Loan growth near 25%: NBFC revenue rose 25% in the quarter. If disbursement momentum holds, lending profit compounds on a larger base each quarter.
- Housing finance reaching scale: a 2.12% return on assets on a ₹57,373 crore book gives ABCL a second lending engine that now earns close to mature peers.
- Health insurance premiums: gross written premium rose 46%. As the book matures, claims ratios usually settle, and profit tends to follow premium with a lag.
- Return on equity: a move from 14.2% to 15.9% in a year, if sustained above 15%, supports a higher multiple on book value.
ABCL also tends to move with the Nifty Financial Services index., so a supportive rate cycle helps both loan growth and valuation.
Key Risks Flagged in the Aditya Birla Capital Analyst Review 2027
The Aditya Birla Capital analyst review 2027 also has a cautious side:
- Balance sheet gearing: debt to equity stands at about 4.6 times. That is normal for a lender, but it means credit losses or funding cost spikes hit equity faster.
- Cash flow: operating cash flow was negative ₹36,544 crore in FY26, which is what a fast-growing lender looks like. The risk is that growth needs continuous fund raising.
- Soft segments: the AMC and health insurance results both slipped in Q2 FY27. If these keep weakening, lending has to carry more of the load.
- Valuation: a P/E of about 24 compares with an industry figure near 18. The premium assumes the higher return on equity lasts.
- Thin, dated coverage: only two verified targets exist, and neither reflects Q2. Any Aditya Birla Capital share price target 2027 discussion is therefore working from limited data.
Compare Aditya Birla Capital With NBFC and Insurance Peers on the Univest Screener
Aditya Birla Capital Analyst Review 2027: Stock at a Glance
| Metric | Value |
|---|---|
| Share Price (16 Nov 2026 close) | ₹408.50 |
| 52-Week High / Low | ₹430.70 / ₹287.70 |
| Market Capitalisation | ₹1,11,689 crore |
| P/E (TTM) vs Industry | 24.3 vs 18.0 |
| Price to Book | 2.62 |
| Book Value per Share | ₹155.90 |
| Return on Equity (TTM) | 10.35% |
| Debt to Equity | 4.62 |
| FY26 Revenue / Net Profit | ₹45,617 crore / ₹3,864 crore |
The 10.35% trailing return on equity uses the full equity base, while the 15.9% quoted in this Aditya Birla Capital analyst review 2027 is the annualised quarterly figure.
Shareholding Trend: Foreign Funds Are Adding
| Holder | Sep 2025 | Mar 2026 | Sep 2026 |
|---|---|---|---|
| Promoters | 68.70% | 68.51% | 68.82% |
| Foreign Institutions (FII) | 6.78% | 7.70% | 8.92% |
| Domestic Institutions (DII) | 12.83% | 13.82% | 13.38% |
| Public | 11.69% | 9.96% | 8.87% |
The clearest trend is foreign buying: FII holding rose by more than two percentage points in a year, while retail public holding shrank. The promoter group held steady near 69%. In this Aditya Birla Capital analyst review 2027, that pattern reads as institutions accumulating a stock that individual holders have been selling into strength.
What to Watch After the Aditya Birla Capital Analyst Review 2027
- Post-results brokerage notes: fresh targets that factor in the 38% profit growth will reshape the Aditya Birla Capital share price target 2027 range.
- Q3 FY27 loan growth: whether NBFC revenue growth stays near 25%.
- Health insurance profitability: premium growth is strong; the next test is the claims ratio.
- AMC flows: a recovery in the asset management result would remove one drag.
- Credit costs: any uptick in stage 3 assets would challenge the bullish case quickly.
Conclusion: Aditya Birla Capital Analyst Review 2027
The Aditya Birla Capital analyst review 2027 describes a group whose lending and housing finance arms are now earning at the level investors had been promised, while the fee businesses are going through a quieter patch. Profit rose 38% and return on equity reached 15.9%, which is a strong base for 2027.
The weakness in the Aditya Birla Capital analyst review 2027 is the evidence on targets. Only two dated calls could be verified, and the more recent one, ₹480 from Motilal Oswal, implies about 17% upside. With the stock close to its high and a P/E above the industry, the next round of research will decide whether the Aditya Birla Capital stock outlook 2027 stays as positive as the quarter suggests. Univest does not give a buy or sell call on the stock.
Disclaimer: This article is for educational and informational purposes only and is not investment advice or a recommendation to buy, sell or hold any security. Brokerage ratings and target prices quoted here are opinions of third-party research houses; Univest does not endorse them and gives no buy or sell call. Investments in the securities market are subject to market risks. Read all related documents carefully before investing. Research Analyst: Uniresearch Global Pvt. Ltd., SEBI Registration No. INH000013776.
Frequently Asked Questions
What does the Aditya Birla Capital analyst review 2027 show?
It shows a strong Q2 FY27, with consolidated profit after tax up 38% to ₹1,288 crore and revenue up 31% to ₹16,545 crore. Return on equity improved to 15.9% from 14.2% a year earlier. Only two dated brokerage targets could be verified, and both predate these results.
What is the Aditya Birla Capital share price target 2027 from brokerages?
Motilal Oswal has a Buy rating with a ₹480 target from August 2026. Sharekhan has a Positive view with a ₹407 target from March 2026. Against the ₹408.50 close on 16 November 2026, that is roughly 17% upside on the higher figure and almost none on the lower one.
Which business drove the profit growth in the Aditya Birla Capital analyst review 2027?
Lending was the main driver, with NBFC gross revenue up 25% to ₹5,179 crore. Housing finance assets reached ₹57,373 crore with a 2.12% return on assets. Health insurance premiums grew 46%, though its quarterly result dipped.
Is Aditya Birla Capital expensive, according to the Aditya Birla Capital analyst review 2027?
The stock trades at a P/E of about 24.3 against an industry P/E near 18.0. Its price to book is about 2.62 times on a book value of ₹155.90 per share. The premium reflects its mix of lending, insurance and asset management businesses and its improving return on equity.
How has shareholding changed in the Aditya Birla Capital analyst review 2027 period?
The promoter group held 68.82% in September 2026, with Grasim Industries alone owning 52.99%. Foreign institutions raised their holding to 8.92% from 6.78% a year earlier. Domestic institutions held 13.38%, and the public held 8.87%.
What are the main risks for the Aditya Birla Capital stock outlook 2027?
Debt to equity of about 4.6 times means credit losses would hit equity quickly. Operating cash flow was negative ₹36,544 crore in FY26 because the loan book is growing fast. The AMC and health insurance results also weakened in Q2 FY27, and the stock already trades about 5% below its 52-week high of ₹430.70.
What should investors track after the Aditya Birla Capital analyst review 2027?
The first item is fresh brokerage notes that include the Q2 FY27 numbers, since the current ₹480 target dates from August 2026. The second is whether NBFC revenue growth near 25% continues in Q3 FY27. Credit costs, health insurance claims and asset management flows round out the list.
Recent Articles

Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
17 November 2026

Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
17 November 2026

AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
17 November 2026

A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
17 November 2026
Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.
Reviews
Recent Posts
Aarti Drugs Analyst Review 2027: Record Quarter, Profit Up 83% and a P/E Half the Industry's
Aakash Exploration Services Analyst Review 2027: Sales Up 9% but a Q2 Loss. Can This ₹8 Oilfield Stock Recover?
AAA Technologies Analyst Review 2027: New Owners, a ₹101 Open Offer and a Stock Now Below It
A2Z Infra Engineering Analyst Review 2027: Revenue Down 31%, Stock Near Its Low and an Auditor Warning
63 moons technologies Analyst Review 2027: Cyber Arm Lifts Guidance to ₹600 Crore, But the Group Still Loses Money
Popular this week
5Paisa Capital Analyst Review 2027: Revenue Up 12%, Profit Down 26% and an MTF Book Growing 32%

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited
Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003
Write to us : support@univest.in, compliance@univest.in
Verify on SEBI registry →RESEARCH ANALYST
Get SEBI Registered
advice on the stocks
trending today.
Get 3 FREE Trade Ideas
for Startups Accelerator 2024
Trusted by 1Cr Indians
Awarded No.1 by Economic Times





